Table 1 Baseline characteristics

Number of lesions

337 (51%)

320 (49%)

N/A

Age [years, Mean (SD)]^b

63.83 (10.75)

64.38 (11.43)

0.5281

Sex^b

0.5707

 Male

179 (53%)

176 (55%)

 Female

158 (47%)

144 (45%)

Lesion size [mm, Mean (SD)]

23.13 (14.90)

27.10 (23.13)

<  0.001

Lesion location

0.0894

 Upper

98 (29%)

74 (23%)

 Lower

239 (71%)

246 (77%)

 Aspirin

62 (18.3%)

56 (17.5%)

0.7903

 NSAIDs

31 (9.3%)

20 (6.1%)

0.1209

 Anti-platelets

6 (1.8%)

16 (5.1%)

0.0209^a

 Anti-coagulants

12 (3.6%)

9 (2.9%)

0.5968^a

 Adenoma

186 (55.19%)

196 (61.25%)

0.1157

 Hyperplastic

18 (5.34%)

10 (3.13%)

0.1598

 Serrated Adenoma

37 (10.98%)

29 (9.06%)

0.4140

 Adenocarcinoma

17 (5.04%)

36 (11.25%)

0.0035

 Hamartoma

1 (0.30%)

0 (0.00%)

> 0.9999

 Barrett’s

5 (1.48%)

10 (3.13%)

0.1592

 Barrett’s Carcinoma

4 (1.19%)

5 (1.56%)

0.7466

 Pancreatic Heterotopia

5 (1.48%)

1 (0.31%)

0.2175

 Neuroendocrine/Carcinoid Tumor

28 (8.31%)

8 (2.50%)

0.0011

 Gastric Heterotopia of Rectum

1 (0.30%)

0 (0.00%)

> 0.9999

 Gastrointestinal Stromal Tumor

6 (1.78%)

1 (0.31%)

0.1239

 Granular Cell Tumor

1 (0.30%)

5 (1.56%)

0.1145

 Gastric Intestinal Metaplasia

5 (1.48%)

2 (0.63%)

0.4517

 Leiomyoma

2 (0.59%)

1 (0.31%)

> 0.9999

 Inflammatory

4 (1.19%)

2 (0.63%)

0.6867

 Lipoma

6 (1.78%)

3 (0.94%)

0.5061

 Squamous Cell Carcinoma

0 (0.00%)

2 (0.63%)

0.2368

 Hemangioma

3 (0.89%)

0 (0.00%)

0.2494

 Brunner’s Gland Hyperplasia

1 (0.30%)

1 (0.31%)

> 0.9999

 Other

7 (2.08%)

8 (2.50%)

0.7168